12,372 trials
Central Precocious Puberty
Primary: Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6 — 93.18 percentage of…
Diabetes Mellitus, Type 2
Primary: Time to 99% Inhibition of Serum Thromboxane — 26.71; 64.57 hours
Diabetes Mellitus, Type 2
Primary: Time to 99% Inhibition of Serum Thromboxane (TxB2) — 12.36; 16.65; 48.64 Hours
Lymphoma
Primary: Failure-free Survival at 5 Years — 0.74; 0.71 Proportion of patients — p=0.32
Breast Cancer
Primary: Progression-free Survival (PFS) Assessed by the Independent Review Panel According to Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 — 166; 165 days…
Stress Disorders, Post-Traumatic
Primary: Clinician-Administered PTSD Scale (CAPS) Diagnostic and Statistical Manual, 4th ed., Text Revision (DSM-IV) — 77.46; 75.61; 52.39; 62.07 units on a scale — p=<.006
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24 — -0.15; 2.46; 2.85 percent predicted of FEV1 — p=0.0004
Obstructive Sleep Apnea · Stroke · Transient Ischemic Attack
Primary: Sleep Apnea Diagnosis Rate — 58; 5 participants
Schizophrenia
Primary: Change From Baseline in PANSS Total Score at Day 42 — -17.4; -21.7; -21.6; -16.2 score on a scale — p=0.6043
Behcet Disease
Primary: Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment — 7.7; 11.5; 7.7 Ocular Exacerbations
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis — -5; -20.5; -44.1; -4.8 percent change — p=< 0.0001
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24 — -0.44; 3.59; 2.16 percent predicted of FEV1 — p=<0.0001
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events — 14; 3; 6; 6 participants
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis — -14.6; -45.0 percent change — p=<0.0001
Myeloid Leukemia, Chronic, Chronic-Phase
Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants